Agreement with Universitat Autònoma de Barcelona (UAB) in drug discovery for Parkinson disease

The Universitat Autònoma de Barcelona (UAB) and Pharmacelera have reached an agreement to perform a research project in the area of Parkinson based on the work led by Dr. Salvador Ventura and developed at Institut de Biotecnologia i Biomedicina (IBB). PharmScreen®, Pharmacelera’s flagship software, will be used to perform screening campaigns in huge virtual libraries to seek new candidate molecules.

“In silico screening technologies will be a key complement to our experimental expertise”, says Salvador Ventura, director of IBB. “PharmScreen® will help us to guide the subsequent steps towards improving the quality of new potential candidates against Parkinson disease. Pharmacelera has put in place a suitable technology for drug discovery purposes, making the whole screening cascade more efficient and saving time and efforts” he adds.

“We are excited to start this project with Institut de Biotecnologia i Biomedicina at UAB and lead by Dr. Ventura, a key player in neuro-degenerative research” says Enric Gibert, CEO of Pharmacelera. “PharmScreen® will play a key role to propose new candidates to be used in the frame of Parkinson’s disease. Pharmacelera has extensive experience in similar drug discovery projects, and we are sure to keep helping the scientific community within this specific project” he adds.

Comments are closed.